Beta Bionics CFO Stephen Feider sells 744 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Beta Bionics, Inc. (BBNX) Chief Financial Officer Stephen Feider exercised 744 options on November 9, 2026, at $5.10 per share, acquiring 744 common shares, then sold 744 shares at a weighted average of $17.001344 per share. The sale was made under a Rule 10b5-1 plan adopted July 31, 2026. His reported option position after the exercise was 38,569.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F3 | 744 | $0.00 | $0.00 |
| Exercise | Common Stock | 744 | $5.10 | $4K |
| Sale | Common Stock F1, F2 | 744 | $17.0013 | $13K |
Footnotes (3)
- F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2026.
- F2. The weighted average sale price for the transaction reported was $17.001344 and the range of prices were between $17.00 and $17.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Key Figures
Key Terms
Rule 10b5-1 Plan regulatory
weighted average sale price financial
vest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many BBNX options did Stephen Feider exercise?
How do Stephen Feider's BBNX options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.